JP2002500017A5 - - Google Patents

Download PDF

Info

Publication number
JP2002500017A5
JP2002500017A5 JP2000526662A JP2000526662A JP2002500017A5 JP 2002500017 A5 JP2002500017 A5 JP 2002500017A5 JP 2000526662 A JP2000526662 A JP 2000526662A JP 2000526662 A JP2000526662 A JP 2000526662A JP 2002500017 A5 JP2002500017 A5 JP 2002500017A5
Authority
JP
Japan
Prior art keywords
bacterium
promoter
host cell
attenuated
structural gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000526662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002500017A (ja
Filing date
Publication date
Priority claimed from US08/999,391 external-priority patent/US6143551A/en
Application filed filed Critical
Publication of JP2002500017A publication Critical patent/JP2002500017A/ja
Publication of JP2002500017A5 publication Critical patent/JP2002500017A5/ja
Pending legal-status Critical Current

Links

JP2000526662A 1997-12-29 1998-12-18 弱毒化した自殺細菌によるマクロファージの細胞質への、ポリペプチドをコードするプラスミドｄｎａの輸送 Pending JP2002500017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/999,391 1997-12-29
US08/999,391 US6143551A (en) 1997-12-29 1997-12-29 Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
PCT/EP1998/008345 WO1999034007A1 (en) 1997-12-29 1998-12-18 Delivery of polypeptide-encoding plasmid dna into the cytosol of macrophages by attenuated suicide bacteria

Publications (2)

Publication Number Publication Date
JP2002500017A JP2002500017A (ja) 2002-01-08
JP2002500017A5 true JP2002500017A5 (https=) 2006-01-12

Family

ID=25546276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000526662A Pending JP2002500017A (ja) 1997-12-29 1998-12-18 弱毒化した自殺細菌によるマクロファージの細胞質への、ポリペプチドをコードするプラスミドｄｎａの輸送

Country Status (11)

Country Link
US (2) US6143551A (https=)
EP (1) EP1042495A1 (https=)
JP (1) JP2002500017A (https=)
KR (1) KR100606322B1 (https=)
AU (1) AU753888B2 (https=)
BR (1) BR9814546A (https=)
CA (1) CA2317111A1 (https=)
HU (1) HUP0100994A3 (https=)
IL (2) IL136455A0 (https=)
PL (1) PL194123B1 (https=)
WO (1) WO1999034007A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242520A1 (en) * 1997-09-06 2004-12-02 Mayo Foundation For Medical Education And Research, A Minnesota Corporation Expression of immonogenic substances
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
DE19949594A1 (de) * 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
AU2003240505A1 (en) * 2002-06-05 2003-12-22 Iowa State University Research Foundation, Inc. Bacteriophage and enzymes lytic to salmonellae
US20050214264A1 (en) * 2002-12-13 2005-09-29 Cosenza Lawrence W Sacromastigophoric therapeutic agent delivery system
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
KR101173871B1 (ko) * 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
DE10326189A1 (de) * 2003-06-06 2005-01-05 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe
US7390646B2 (en) * 2003-09-17 2008-06-24 The Regents Of The University Of California Bacterial vectors and methods of use thereof
US20070298012A1 (en) * 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
EP1799937A1 (en) 2004-07-23 2007-06-27 Henkin-Laby, LLC Swimming pool cleaner debris container
WO2006137836A2 (en) * 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
US20090123426A1 (en) 2004-12-17 2009-05-14 Chiang Li Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI658140B (zh) * 2015-11-12 2019-05-01 昕穎生醫技術股份有限公司 表現異源基因的系統及其用途
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2255561B (en) * 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
DE59510532D1 (de) * 1994-09-09 2003-02-20 Biotec Lab Ltd Aufschluss von bakterienzellen durch phagenlysine
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
IL123569A (en) * 1995-09-06 2006-10-05 Dept Of The Army Attenuated shigella strain for delivering a mamalian expression plasmid into a mammalian cell
DE19754938B4 (de) * 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC-Verfahren zur Induktion einer zielgerichteten, somatischen Transgenität

Similar Documents

Publication Publication Date Title
JP2002500017A5 (https=)
AU2017297610B2 (en) Compositions and methods for alphavirus vaccination
EP1303299B1 (en) Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens
US10835596B2 (en) Compositions and methods for flavivirus vaccination
US20160215039A1 (en) Agents and methods based on the use of the eda domain of fibronectin
US20120100170A1 (en) Compositions and methods for the treatment of hepatitis c
US20080248068A1 (en) Use of Flagellin as an Adjuvant for Vaccine
EP2207567B1 (en) Immunogenic formulation
TWI221847B (en) Clostridium perfringens vaccine
Sefat et al. An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis
JP7686302B2 (ja) 融合遺伝子、組換え新型コロナウイルス高効率免疫ｄｎａワクチン、それらの構築方法及び使用
González-Smith et al. Evaluation of Brucella abortus DNA vaccine by expression of Cu–Zn superoxide dismutase antigen fused to IL-2
Gholami et al. Delivery systems for Leishmania vaccine development
CA2406225C (en) Recombinant intracellular pathogen vaccines and methods for use
CA2556229A1 (en) System immune activation method using non cpg nucleic acids
Medina et al. Modulation of host immune responses stimulated by Salmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen
JP5685646B2 (ja) リポソーム中にカプセル化されたスチコリシンに基づくワクチン組成物
TW201809274A (zh) 蛋白質表現強化子序列及其用途
US20020086837A1 (en) Acne vaccine
KR102900668B1 (ko) 결핵 항원을 포함하는 mRNA 구조체 및 이를 포함하는 약학 조성물
KR102259933B1 (ko) 포자 표면발현을 이용한 탄저 포자 백신의 제조방법 및 탄저 포자 백신
Tabbara Antigen Requirements for Efficient Priming of CD8+ T Cells by Leishmania major-Infected Dendritic Cells
WO2024216060A1 (en) Mucosal vaccines against tuberculosis
APCs Mucosally Delivered Dendritic Cells Activate
HK1190757B (en) Methods and compositions for inducing an immune response to egfrviii